UCB’s CIMZIA© approved for potential use in women with AS during breastfeeding and pregnancy

The European Medicines Agency (EMA) has approved the label change for UCB’s CIMZIA© (certolizumab pegol), making it the first anti-TNF for potential use in women with Ankylosing Spondylitis during both pregnancy and breastfeeding.

Full Press Release

Other NEWS

Intimacy and AS

Michael Mallinson has lived with AS for over 35 years. He developed this content as a consultant to Novartis Ph

Read More
Sculpture Exhibition “Disease of Young People or Life with Pain” in Moscow

From 4 to 13 December, the Ankylosing Spondylitis Association of the Russian Federation created a sculpture exhibit

Read More